Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 10/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646998 | 0.87 | CASP1 (0.53) | ADRB2ADRB1ADRB3CASP1KDM4E | |
| SCHEMBL1410130 | 0.84 | ADRB2 (0.44) | ADRB2ADRB1ADRB3CASP1KDM4E | |
| SCHEMBL1410128 | 0.84 | ADRB2 (0.44) | ADRB2ADRB1ADRB3CASP1KDM4E | |
| SCHEMBL1410176 | 0.83 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL311041 | 0.83 | KLK5 (0.36) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL10201585 | 0.80 | ADRB2 (0.46) | ADRB2ADRB1ADRB3CASP1ALDH1A1 | |
| SCHEMBL1409882 | 0.79 | ADRB2 (0.48) | ADRB2ADRB1ADRB3CASP1KDM4E | |
| SCHEMBL5831798 | 0.78 | KLK5 (0.50) | CASP1ALDH1A1 | |
| SCHEMBL10201588 | 0.76 | POLB (0.44) | KDM4EALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL7344489 | 0.75 | CYP2D6 (0.43) | CASP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ADRB2 3689/4885ADRB1 2121/4885ADRB3 3557/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ADRB2 3689/4885ADRB1 2121/4885ADRB3 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.